Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 112-117

  Rubio, Thomas T ^a,d   Miles, Michael V ^a   Lettieri, John T ^c   Kuhn, Robert J ^b   Echols, Roger M ^c   Church, Deborah A ^c  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c BAYER CORPORATION   (United States)

^d CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

Author keywords

ciprofloxacin; Cystic fibrosis; intravenous; oral; pediatrics; pharmacokinetics

Indexed keywords

CIPROFLOXACIN;

ADOLESCENT; ANTIBIOTIC THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYSTIC FIBROSIS; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-INFECTIVE AGENTS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; CYSTIC FIBROSIS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS;

EID: 0031048805     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00033     Document Type: Conference Paper

References (27)

1. Burns JL, Ramsey BW, Smith AL. Clinical manifestations and treatment of pulmonary infections in cystic fibrosis. Adv Pediatr Infect Dis 1993;8:53-66.
2. Kurz CC, Marget W, Harms K, Bertele RM. Vergleichende Untersuchung mit Ciprofloxacin und Ofloxacin im Kreuzversuch bei zystischer Fibrose. Fortschr Antimikrob Antineoplast Chemother 1987;6;2107-13.
3. Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med 1989;87(Suppl 5A):123-7.
4. Strandvik B, Hjelte L, Lindblad A, Ljungberg B, Malmborg AS, Nilsson-Ehle I. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection. Scand J Infect 1989;60:84-8.
5. Church DA, Kanga JF, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997;16:97-105.
6. Bergogne-Berezin E. Pharmacokinetics of antibiotics in cystic fibrosis patients with particular reference to the bronchopulmonary tree. Infection 1987;15:288-94.
7. Goldfarb J, Wormser G, Inchiosa M, et al. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis. J Clin Pharmacol 1986;26:222-6.
8. Davis R, Koup J, Williams-Warren J, et al. Pharmacokinetics of ciprofloxacin in cystic fibrosis. Antimicrob Agents Chemother 1987;31:915-9.
9. Reed M, Stern R, Myers C, Yamashita T, Blumer J. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol 1988;28:691-9.
10. LeBel M. Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988;8:3-33.
11. Gershwin E. Pharmacokinetics of drugs in cystic fibrosis. Clin Rev Allergy 1991;9:169-209.
12. Spino M, Bentur Y, Martin S, et al. Enoxacin disposition in patients with cystic fibrosis and healthy control subjects [Abstract OP27.03]. Eur J Clin Pharmacol 1989;36(Suppl): A84.
13. Krol GJ, Noe AJ, Beermann D. Liquid chromatographic analysis of ciprofloxacin and ciprofloxacin metabolites in body fluids. J Liquid Chromatogr 1986;9:2897-919.
14. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Dekker, 1982.
15. DeGroot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Clin Pharmacokinet 1987;13:228-53.
16. Finkelstein E, Hall K. Aminoglycoside clearance in patients with cystic fibrosis. J Pediatr 1979;94:163-4.
17. Jusko W, Mosovich LL, Gerbracht LM, Matter ME, Yaffe SJ. Enhanced renal excretion of dicloxacillin patients with cystic fibrosis. Pediatrics 1975;56:1038-44.
18. Rane A, Wilson JT. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet 1976;1:2-24.
19. Prandota J. Clinical pharmacokinetics of changes in drug elimination in children. Dev Pharmacol Ther 1985;8:311-28.
20. Morselli P, Franco-Morsell R, Bossi L. Clinical pharmacokinetics in newborns and infants. Clin Pharmacokinet 1980;5: 485-527.
21. Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection 1986;14:23-7.
22. LeBel M, Bergeron MG, Vallee F. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1986;30:260-6.
23. Christensson B, Nilsson-Ehle I, Ljungberg B, et al. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients. Antimicrob Agents Chemother 1992;36:2512-7.
24. Peltola H, Vaarala M, Renkonen OV, Neuvonen PJ. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother 1992;36:1086-90.
25. Tartaglione TA, Raffalovich AC, Poynor WJ, et al. Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing doses. Antimicrob Agents Chemother 1986;29: 62-6.
26. Wise R, Donovan IA. Tissue penetration and metabolism of ciprofloxacin. Am J Med 1982;82(Suppl 4A):103-7.
27. Rohwedder R, Bergan T, Thorsteinsson SB, Scholl H. Transintestinal elimination of ciprofloxacin. Chemotherapy 1990;36:77-84.